Company Brief
What the company does
Oncolys BioPharma Inc. engages in the research, development, manufacturing, sale, and import of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the United States, and Asia. Its product pipeline comprises Telomelysin (OBP-301), an oncolytic viral immunotherapy which is in phase II clinical trial to treat gastric cancer; phase I clinical trial for the treatment of HCC; and treatment of esophageal cancer. The company also develops OBP-601(Censavudine), which is in phase II clinical trial to treat progressive supranuclear palsy, amyotrophic lateral sclerosis, and aicardi-goutieres syndrome; OBP-702, which is in preclinical trial to treat …